Last reviewed · How we verify
NCT06962098: PROMISS-DKD
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
Phase 2 trial testing Isuzinaxib in Diabetic Kidney Disease (DKD) in 186 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Aptabio Therapeutics, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 186 |
| Start date | 26 May 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2028 |
| Sites | 20 locations across South Korea |
Drugs / interventions tested
- Isuzinaxib — full drug profile →
- Placebo
Conditions studied
- Diabetic Kidney Disease (DKD) — all drugs for Diabetic Kidney Disease (DKD) →
Sponsor
Aptabio Therapeutics, Inc. — full company profile →
Who can join
19 and older, any sex, with Diabetic Kidney Disease (DKD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, double-blinded, randomized, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, PK, and efficacy of Isuzinaxib compared with placebo in subjects with DKD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06962098
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Kidney Disease (DKD)
Currently open trials in the same condition.
- NCT07271186 — Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidn · Phase 2 · recruiting
- NCT07348718 — Rubix LS Diabetic Kidney Disease (DKD) Registry Study · active not recruiting
- NCT06969807 — Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease · Phase 2 · recruiting
- NCT06866158 — Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease · Phase 1, PHASE2 · active not recruiting
Other Aptabio Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05758896 — Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI · Phase 2 · recruiting
- NCT04880109 — A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19. · Phase 2 · terminated
- NCT04534439 — Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy · Phase 2 · completed
- NCT03694041 — Safety, Tolerability, PK and PD of SAD or MAD of APX-115 in Healthy Male Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06962098 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aptabio Therapeutics, Inc.
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06962098.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing